07
Nov
2014
00:00
GMT
Webinar
TAVI: Why Are We Conducting Randomised Trials in Intermediate Risk Patients?
-
Views:
2338
-
Likes:
0
Overview
This webinar mainly focusses on how TAVI has developed since inception, contemporary best practice and associated data, and areas that require further development in the future and the rationale behind this.
Participants attending this webinar will:
- Update their scientific knowledge
- Improve their clinical practice
Faculty:
Simon Kennon
Educational Objective
- Historical AVR outcomes
- Randomised trials in high-risk patients
- The evolution of TAVI procedures
- Improving outcomes in high-risk registries
- Contemporary AVR outcomes
- Randomised trials in intermediate-risk patients
Target Audience
- Interventional cardiologists
- Cardiac surgeons
- Other cardiologists wishing to update their scientific knowledge on the topic
Faculty Biographies
Simon Kennon
Dr Simon Kennon qualified from Manchester Medical School in 1992. He completed general medical training in and around London (Royal Free Hospital, Southend General Hospital, Newham General Hospital and the London Chest Hospital) before training in General and Interventional Cardiology at St Bartholomew’s, and the London Chest Hospitals. His training continued with a fellowship in interventional cardiology at St Vincent's Hospital, Melbourne, Australia.
He was appointed as a Consultant Cardiologist in 2005. His NHS work is divided between the London Chest Hospital (Barts Health NHS Trust) and Barnet & Chase Farms Hospital NHS Trust.
His private practice is based at the King’s Oak Hospital, the Cavell Hospital and the London Independent Hospital.
Dr Kennon is experienced in the management of all general cardiology conditions (including palpitations, high blood pressure, high cholesterol), but his special interests are the assessment and treatment of chest pain and aortic valve disease. He is an experienced TAVI operator having set up and led the TAVI Programme at the London Chest Hospital for the last 4 years. He is also an interventional cardiologist performing coronary interventions in both elective and emergency settings.
His research interests include TAVI, aortic valve disease and acute coronary syndromes, about which he has published many scientific papers. He lectures at national and international meetings and has performed coronary angioplasty live for training purposes at international meetings, both in Europe and America (EuroPCR, TCT).
Key References
1. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010;21:363.
2. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011;9:2187–98.
3. Fröhlich GM, Lansky AJ, Webb J, et al. Local versus general anesthesia for transcatheter aortic valve implantation (TAVR) - systematic review and meta-analysis. BMC Med. 2014;12(1):41. [Epub ahead of print]
4. Yamamoto M, Meguro K, Mouillet G et al. Effect of local anesthetic management with conscious sedation in patients undergoing transcatheter aortic valve implantation. Am J Cardiol. 2013;111(1):94-9.
5. Hamm CW, Möllmann H, Holzhey D, et al. The German Aortic Valve Registry (GARY): in-hospital outcome. Eur Heart J 2013 Sep 10. doi:10.1093/eurheartj/ eht381
6. Gilard M, Eltchaninoff H, Iung B, et al. Registry of transcatheter aortic-valve implantation in high-risk patients. N Engl J Med 2012;366:1705–15.
7. Durand E, MD, Borz B, Godin M et al. Transfemoral Aortic Valve Replacement With the Edwards SAPIEN and Edwards SAPIEN XT Prosthesis Using Exclusively Local Anesthesia and Fluoroscopic Guidance. J Am Coll Cardiol 2012;5:461-7.
8. Thomas M, Schymik G, Walther T, et al. Thirty-day results of the SAPIEN aortic bioprosthesis European outcome (SOURCE) registry: a European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation 2010;122:62–9.
9. Rodés-Cabau J, Webb JG, Cheung A, et al. Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience.
10. J Am Coll Cardiol 2010;55:1080–90.
11. Petronio A, De Carlo M, Bedogni F et al. Safety and Efficacy of the Subclavian Approach for Transcatheter Aortic Valve Implantation With the CoreValve Revalving System′ Circ Cardiovasc Interv. 2010;3:359-366.
12. Anon. Percutaneous balloon aortic valvuloplasty. Acute and 30-day follow-up results in 674 patients from the NHLBI Balloon Valvuloplasty Registry. Circulation. 1991;84(6):2383–2397.
13. Awad W, Mathur A, Baldock L, Oliver S, Kennon S. Comparing post-operative resource consumption following transcatheter aortic valve implantation (TAVI) and conventional aortic valve replacement in the UK. J Med Econ. 2014 May;17(5):357-64.